Pharmacyte Biotech Inc (OTCMKTS:PMCB) stated that the company have made a deal with Imaging Endpoints to perform radiologic imaging. It is one of the initial requirements for conducting Phase 2b clinical study in pancreatic cancer. The Chief Executive, Kenneth L. Waggoner, stated that they are extremely pleased to contract with Imaging Endpoints. The entity will conduct some of the most critical measure pertaining to the upcoming clinical trial in pancreatic cancer.
The CEO added that the success of this study targeting pancreatic cancer will be crucial for the success of company. The outstanding team linked with Imaging Endpoints and the company’s expertise in assessing the radiologic imaging data from the study will ensure that the result interpretation is both accurate and comprehensive.
On Wednesday, the stock price of Pharmacyte gained over 3% to close at $0.0940 on share volume of 1.13 million.
Nutra Pharma Corp. (OTCMKTS:NPHC) RPI-78M Attains Orphan Drug Status
Nutra Pharma Corp. (OTCMKTS:NPHC) revealed that the company has received Orphan Drug status for its lead drug candidate known as RPI-78M. The potential drug targets Multiple Sclerosis in children. The CEO Rik J. Deitsch said that receiving orphan drug status by the FDA is a remarkable achievement for them. Multiple Sclerosis in children is a major disease segment that does not have any effective treatments available in the market.
Depending on open label studies and pre-clinical trials based on RPI-78M, Nutra Pharma believes that RPI-78M drug can get through the approval process. After the orphan drug status, the company plans to prepare an investigative NDA with the U.S. FDA and move forward with the clinical trial protocols to get drug approval.
Growblox Sciences Inc (OTCMKTS:GBLX) disclosed that the company appointed Sandra Tiffany as new GM. Ms. Tiffany is a formed Nevada State Senator and has been on various leadership roles.
